Results from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
?An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. The most common side effects were injection site pain and transient fever that appeared and resolved within 12 to 36 hours after vaccination. A report describing preliminary results of the NIH-WRAIR study appears online today in The New England Journal of Medicine. The VSV-ZEBOV candidate is one of two experimental Ebola vaccines now being tested in the phase 2/3 PREVAIL clinical trial that is enrolling volunteers in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
Scientists at the Public Health Agency of Canada developed the candidate vaccine. It was licensed to NewLink Genetics Corp. of Ames, Iowa, a company collaborating with Merck & Co. Inc., of Kenilworth, New Jersey, which is responsible for advancing this vaccine towards regulatory approval. The investigational vaccine is based on a genetically modified and attenuated vesicular stomatitis virus (VSV), a virus that mainly affects cattle. In the investigational vaccine, a gene for a VSV protein is replaced with a gene segment from a key protein in the Zaire species of Ebola virus. The vaccine does not contain the whole Ebola virus and therefore cannot infect vaccinated persons with Ebola.
The new report summarizes results of the first 52 volunteers enrolled in the study: 26 at the NIH Clinical Center in Bethesda, Maryland, and 26 at the WRAIR clinic in Silver Spring, Maryland. Six volunteers at each site received a placebo injection of saline solution, and the remaining 40 received the experimental vaccine at either one of two different dosages (2 x107 or 3 x106 in 20 volunteers at each site). The NIH trial was led by NIAID investigators Richard T. Davey, Jr., M.D., and John H. Beigel, M.D., while Jason A. Regules, M.D., and Stephen J. Thomas, M.D., headed the trial at WRAIR.
The candidate vaccine’s ability to stimulate immune responses was assessed by sampling the volunteers’ blood at multiple time points following injection. (The blood sampling schedule differed between the two trial sites.) Of those volunteers tested at 14 days after injection, 93 percent (26 out of 28) of whose who had received vaccine developed antibodies against Zaire species of Ebola virus. Antibodies were detected in the remaining 14 volunteers who had received vaccine by 28 days after injection. Antibody responses were approximately three-fold greater in those who received the higher vaccine dose. This information was available to the designers of the PREVAIL trial and was used to guide the decision to use VSV-ZEBOV at the higher dosage level in that trial.
“The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions,” said Dr. Davey.
The Latest on: Ebola Vaccine
via Google News
The Latest on: Ebola Vaccine
- The Oxford scientists who developed the Covid vaccine in record timeon July 2, 2021 at 9:00 am
There is a new virus in China and Sarah Gilbert, an Oxford scientist, is trying out a novel vaccine technique. The epidemic in China may come to nothing, she tells me, but this is a good ...
- Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Responseon July 1, 2021 at 5:08 pm
Johnson & Johnson (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other ...
- 5 Best Medical Stocks to Invest Inon June 30, 2021 at 10:37 am
In this article we discuss the 5 best medical stocks to invest in. If you want to read our detailed analysis of these companies, go directly to 10 ...
- UH Manoa researchers receive $3M grant to develop vaccine against deadly diseaseon June 27, 2021 at 7:20 pm
Researchers at the University of Hawaii at Manoa’s School of Life Sciences were awarded a $3-million contract from the U.S. Department of Defense to create a vaccine against a disease UH ...
- Devex CheckUp: The long game of producing vaccines locallyon June 24, 2021 at 6:32 am
In today's edition: the challenge of manufacturing medicine and health products locally, the paradox of proving a disease is neglected, and a new mRNA vaccine hub.
- Chinese Drugmaker CanSino Hits Record High After Meningitis Vaccine Approvedon June 23, 2021 at 3:55 am
The Shanghai-listed shares of CanSino Biologics, a Chinese drugmaker well-known for developing a Covid-19 vaccine, surged to an historic high after its meningitis shot was approved for sale in China.
- Guinea declares end to Ebola outbreak that killed 12on June 19, 2021 at 6:32 am
WHO helped ship around 24,000 Ebola vaccine doses that helped inoculate nearly 11,000 people in the region, including over 2,800 frontline health workers. "Although this Ebola outbreak flared up ...
- Ebola Fast Factson June 9, 2021 at 7:25 am
May 9, 2015 – The WHO declares an end to the ... July 31, 2015 – The CDC announces that a newly developed Ebola vaccine is “highly effective” and could help prevent its spread in the ...
via Bing News